[HTML] springer.com

[HTML][HTML] Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects

H Zahir, J Greenberg, D Shuster, C Hsu… - Clinical …, 2022 - Springer
Abstract Background and Objective Pexidartinib is a novel oral small-molecule inhibitor that
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …
被引用次数：4 相关文章

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.

H Zahir, J Greenberg, D Shuster, C Hsu… - Clinical …, 2022 - europepmc.org
Methods Four open-label crossover studies were performed to assess the effects of a pH
modifier (esomeprazole), a strong cytochrome P450 (CYP) 3A4 inhibitor (itraconazole), a …
[HTML] nih.gov

[HTML][HTML] Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects

H Zahir, J Greenberg, D Shuster, C Hsu… - Clinical …, 2022 - ncbi.nlm.nih.gov
Methods Four open-label crossover studies were performed to assess the effects of a pH
modifier (esomeprazole), a strong cytochrome P450 (CYP) 3A4 inhibitor (itraconazole), a …

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects

H Zahir, J Greenberg, D Shuster… - Clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
Background and objective Pexidartinib is a novel oral small-molecule inhibitor that
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects

H Zahir, J Greenberg, D Shuster, C Hsu… - Clinical …, 2022 - search.proquest.com
Abstract Background and Objective Pexidartinib is a novel oral small-molecule inhibitor that
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.

H Zahir, J Greenberg, D Shuster, C Hsu… - Clinical …, 2022 - search.ebscohost.com
Abstract Background and Objective: Pexidartinib is a novel oral small-molecule inhibitor that
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …

[引用][C] Evaluation of Absorption and Metabolism‑Based DDI Potential of Pexidartinib in Healthy Subjects

H Zahir, J Greenberg, D Shuster, C Hsu… - Clinical …, 2022 - europepmc.org
Abstract Background and Objective Pexidartinib is a novel oral small-molecule inhibitor that
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …

[引用][C] Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.

H Zahir, J Greenberg, D Shuster, C Hsu, K Watanabe…